These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 18596668)

  • 1. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy.
    Madeddu G; Spanu A; Chessa F; Calia GM; Lovigu C; Mannazzu M; Falchi A; Sanna D; Mura MS; Madeddu G
    Q J Nucl Med Mol Imaging; 2009 Jun; 53(3):290-301. PubMed ID: 18596668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
    Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
    Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients.
    Seminari E; Castagna A; Soldarini A; Galli L; Fusetti G; Dorigatti F; Hasson H; Danise A; Guffanti M; Lazzarin A; Rubinacci A
    HIV Med; 2005 May; 6(3):145-50. PubMed ID: 15876279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone mineral density remains stable in HAART-treated HIV-infected men over 2 years.
    Bolland MJ; Grey AB; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Woodhouse AF; Gamble GD; Reid IR
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):270-5. PubMed ID: 17547686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential bone metabolism between postmenopausal women with osteoarthritis and osteoporosis.
    Jiang LS; Zhang ZM; Jiang SD; Chen WH; Dai LY
    J Bone Miner Res; 2008 Apr; 23(4):475-83. PubMed ID: 18052758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of serum leptin with age, body weight, body mass index, and bone mineral density in healthy mainland Chinese women.
    Zhong N; Wu XP; Xu ZR; Wang AH; Luo XH; Cao XZ; Xie H; Shan PF; Liao EY
    Clin Chim Acta; 2005 Jan; 351(1-2):161-8. PubMed ID: 15563886
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alterations of bone mineral density and bone metabolism in patients with various grades of chronic pancreatitis.
    Mann ST; Stracke H; Lange U; Klör HU; Teichmann J
    Metabolism; 2003 May; 52(5):579-85. PubMed ID: 12759887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of rosiglitazone on insulin sensitivity, beta cell function, bone mineral density, and body composition in hiv-positive patients on highly-active antiretroviral therapy (HAART).
    Schindler K; Rieger A; Tura A; Gmeinhardt B; Touzeau-Römer V; Haider D; Pacini G; Ludvik B
    Horm Metab Res; 2009 Jul; 41(7):573-9. PubMed ID: 19322744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB; Lindegaard B; Obel N; Andersen O; Nielsen H; Gerstoft J
    HIV Med; 2006 Jan; 7(1):38-45. PubMed ID: 16313291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
    Trento LK; Pietropolli A; Ticconi C; Gravotta E; De Martino MU; Fabbri A; Piccione E
    J Obstet Gynaecol Res; 2009 Feb; 35(1):152-9. PubMed ID: 19215563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stable bone mineral density over 6 years in HIV-infected men treated with highly active antiretroviral therapy (HAART).
    Bolland MJ; Grey A; Horne AM; Briggs SE; Thomas MG; Ellis-Pegler RB; Gamble GD; Reid IR
    Clin Endocrinol (Oxf); 2012 May; 76(5):643-8. PubMed ID: 22040002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
    Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
    Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
    van Vonderen MG; Lips P; van Agtmael MA; Hassink EA; Brinkman K; Geerlings SE; Sutinen J; Ristola M; Danner SA; Reiss P
    AIDS; 2009 Jul; 23(11):1367-76. PubMed ID: 19424051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid function in human immunodeficiency virus patients treated with highly active antiretroviral therapy (HAART): a longitudinal study.
    Madeddu G; Spanu A; Chessa F; Calia GM; Lovigu C; Solinas P; Mannazzu M; Falchi A; Mura MS; Madeddu G
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):375-83. PubMed ID: 16584508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of HIV infection on total body composition in treatment-naive men evaluated by dual-energy X-ray absorptiometry comparison of 90 untreated HIV-infected men to 241 controls.
    Delpierre C; Bonnet E; Marion-Latard F; Aquilina C; Obadia M; Marchou B; Massip P; Perret B; Bernard J
    J Clin Densitom; 2007; 10(4):376-80. PubMed ID: 17888698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Influence of long-term highly active antiretroviral therapy on bone mineral density in HIV/AIDS patients].
    Su YB; Xie J; Han Y; Qiu ZF; Li YL; Song XJ; Yu W; Li TS
    Zhonghua Yi Xue Za Zhi; 2012 May; 92(17):1155-8. PubMed ID: 22883000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral therapy affects the composition of weight loss in HIV infection: implications for clinical nutrition.
    Maia BS; Engelson ES; Wang J; Kotler DP
    Clin Nutr; 2005 Dec; 24(6):971-8. PubMed ID: 16095765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of antiretroviral therapy on visfatin and retinol-binding protein 4 in HIV-infected subjects.
    Schindler K; Haider D; Wolzt M; Rieger A; Gmeinhart B; Luger A; Nowotny P; Ludvik B
    Eur J Clin Invest; 2006 Sep; 36(9):640-6. PubMed ID: 16919047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
    Guo FP; Yu XB; Luo L; Han Y; Qiu ZF; Zuo LY; Li YL; Yu W; Li TS
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BMD is reduced in HIV-infected men irrespective of treatment.
    Amiel C; Ostertag A; Slama L; Baudoin C; N'Guyen T; Lajeunie E; Neit-Ngeilh L; Rozenbaum W; De Vernejoul MC
    J Bone Miner Res; 2004 Mar; 19(3):402-9. PubMed ID: 15040828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.